title: Y-box binding protein-1 is a novel molecular target for tumor vessels.
abstract: Y-box binding protein-1 (YB-1) is a member of the cold shock protein family and functions in transcription and translation. Many reports indicate that YB-1 is highly expressed in tumor cells and is a marker for tumor aggressiveness and clinical prognosis. Here, we show clear evidence that YB-1 is expressed in the angiogenic endothelial cells of various tumors, such as glioblastoma, esophageal cancer, gastric cancer, colon cancer, and lung cancer, as well as in tumor cells. YB-1 was highly expressed in glomeruloid microvascular endothelial cells of brain tumors and microvessels in the desmoplastic region around multiple solid tumors. On the other hand, no or low YB-1 expression was observed in normal angiogenic endothelial cells from fetal kidney, newborn lung, and placenta. The endothelial cells in inflammatory regions of granulomas were also weakly labeled. Knockdown of YB-1 expression by small-interfering RNA induced G1 cell cycle arrest and inhibited the growth of human umbilical vein endothelial cells stimulated by growth factors. Taken together, YB-1 plays an important role in the growth of not only tumor cells but also tumor-associated endothelial cells, suggesting that YB-1 is a promising target for cancer therapy.
authors.affiliation: Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: Mayu
authors.initials: M
authors.lastname: Takahashi
authors.forename: Shohei
authors.initials: S
authors.lastname: Shimajiri
authors.forename: Hiroto
authors.initials: H
authors.lastname: Izumi
authors.forename: Gen
authors.initials: G
authors.lastname: Hirano
authors.forename: Eiji
authors.initials: E
authors.lastname: Kashiwagi
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Yasuniwa
authors.forename: Ying
authors.initials: Y
authors.lastname: Wu
authors.forename: Bin
authors.initials: B
authors.lastname: Han
authors.forename: Masaki
authors.initials: M
authors.lastname: Akiyama
authors.forename: Shigeru
authors.initials: S
authors.lastname: Nishizawa
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Sasaguri
authors.forename: Kimitoshi
authors.initials: K
authors.lastname: Kohno
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000098:blood supply / Q000737:chemistry; D002478:Cells, Cultured; D004268:DNA-Binding Proteins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D042783:Endothelial Cells / Q000502:physiology; D005909:Glioblastoma / Q000098:blood supply / Q000737:chemistry; D006801:Humans; D009369:Neoplasms / Q000098:blood supply*; D009389:Neovascularization, Pathologic; D009687:Nuclear Proteins / Q000032:analysis / Q000037:antagonists & inhibitors / Q000502:physiology*; D051840:Y-Box-Binding Protein 1
chemical_list: D020533:Angiogenesis Inhibitors; D004268:DNA-Binding Proteins; D009687:Nuclear Proteins; D051840:Y-Box-Binding Protein 1; C070856:YBX1 protein, human
references.citation: Cancer Res. 2005 May 15;65(10):4078-87
references.pmid: 15899797
references.citation: Cancer Sci. 2003 Jan;94(1):9-14
references.pmid: 12708467
references.citation: Cancer Res. 2001 Sep 15;61(18):6649-55
references.pmid: 11559528
references.citation: Nucleic Acids Res. 2004 Jan 29;32(2):611-22
references.pmid: 14752049
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1196-208
references.pmid: 17401009
references.citation: Cancer Res. 2006 May 1;66(9):4872-9
references.pmid: 16651443
references.citation: Am J Pathol. 2001 Mar;158(3):1145-60
references.pmid: 11238063
references.citation: Brain. 2007 Dec;130(Pt 12):3336-41
references.pmid: 17998256
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Mol Cancer Ther. 2008 Dec;7(12):3670-84
references.pmid: 19074844
references.citation: J Cell Biochem. 2007 Jul 1;101(4):887-907
references.pmid: 17266048
references.citation: Science. 2000 Aug 18;289(5482):1197-202
references.pmid: 10947988
references.citation: Cancer Res. 1996 Sep 15;56(18):4224-8
references.pmid: 8797596
references.citation: Nature. 2001 May 17;411(6835):375-9
references.pmid: 11357145
references.citation: Nat Rev Cancer. 2008 Aug;8(8):579-91
references.pmid: 18596824
references.citation: Eur J Cancer. 2010 Mar;46(5):954-65
references.pmid: 20079629
references.citation: Mol Cancer Ther. 2004 Nov;3(11):1485-92
references.pmid: 15542787
references.citation: Cancer Res. 2008 Jan 1;68(1):98-105
references.pmid: 18172301
references.citation: Science. 2009 Jun 12;324(5933):1457-61
references.pmid: 19460966
references.citation: Cancer Res. 2004 Oct 1;64(19):6892-9
references.pmid: 15466178
references.citation: Oncogene. 2007 Jul 19;26(33):4749-60
references.pmid: 17297441
references.citation: Nat Med. 2004 Aug;10(8):789-99
references.pmid: 15286780
references.citation: Nature. 2001 May 17;411(6835):355-65
references.pmid: 11357143
references.citation: Mol Cancer Ther. 2009 Dec;8(12):3276-84
references.pmid: 19996271
references.citation: J Biol Chem. 2006 Dec 29;281(52):40440-9
references.pmid: 17082189
references.citation: J Pathol. 2003 Feb;199(2):251-8
references.pmid: 12533839
references.citation: Eur J Cancer. 2005 Nov;41(16):2577-86
references.pmid: 16209921
references.citation: Int J Cancer. 2009 Sep 1;125(5):1222-30
references.pmid: 19431144
references.citation: Curr Med Chem Anticancer Agents. 2005 Jan;5(1):15-27
references.pmid: 15720258
references.citation: Nat Rev Drug Discov. 2007 Apr;6(4):273-86
references.pmid: 17396134
references.citation: Annu Rev Med. 2006;57:1-18
references.pmid: 16409133
references.citation: Bioessays. 2003 Jul;25(7):691-8
references.pmid: 12815724
references.citation: J Neurooncol. 2009 Oct;95(1):13-22
references.pmid: 19381445